Regeneron Pharmaceuticals shares closed 1.43% higher at $718.54 per share on Friday (June 30). The stock outperformed the market on a strong trading day where all three US indices closed in the green. The Dow Jones Industrial Average rose 0.84%, while the S&P 500 index added 1.23%, and the NASDAQ Composite index added 1.45%.

The share price of Regeneron Pharmaceuticals has been on investors’ radar recently because although the share price of the biotech company hasn't performed well, especially in the last quarter, its shareholders are pleased as they have received really good returns over the last five years.

The stock has risen an impressive 102% in the last five years. So, the long-term investors who bought the stock five years back have a reason to be happy.

The returns from the stock have gained nearly 21% in the last one years, while it has fallen 12.55% in the last three months. The company has a market capitalization of $78.83 billion.

One of the popular ways to know how sentiment around a company has changed is to compare its earnings per share (EPS) with its share price.

In five years, Regeneron Pharmaceuticals has managed to increase its EPS by 24% a year. The EPS growth outperforms the yearly share price gain of 20%. This in a way indicates that investors are not so enthusiastic about the stock these days.

Meanwhile, if we look at Regeneron Pharmaceuticals’ total shareholder return of 20% in the last twelve months we realize that this gain is better than the annual TSR over five years, which is 15%. This indicates that the sentiment around the company has been positive lately. 

Last week, the company’s shares fell drastically after the biotech heavyweight revealed that the Food and Drug Administration (FDA) issued a Complete Response Letter (i.e., a rejection) for its high-dose formulation of Eylea. Eylea, a biologic therapy for various eye disorders like wet age-related macular degeneration (wet AMD), generated approximately $6.3 billion in net US sales for the drugmaker in 2022.

However, the positive news in this rejection is that this rejection only stems from a third-party manufacturing issue, according to the press release. Wall Street analysts believe that this regulatory hurdle can be addressed fairly quickly. 

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

The company is expected to announce its second quarter 2023 financial and operating results on Thursday, August 3, 2023, before the US financial markets open.